Anzeige
Mehr »
Freitag, 17.10.2025 - Börsentäglich über 12.000 News
Silber durchbricht 50 US-Dollar - Vizsla Royalties zählt zu den größten Gewinnern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
11.09.Amid restructuring, Novo Nordisk directs employees to return to office
11.09.AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
11.09.Intercept, after many setbacks, pulls liver disease drug Ocaliva in US
11.09.Despite being designed for seniors, Merck's pneumococcal shot shows potential in children
11.09.FibroGen pays SEC $1.2M over allegations former exec 'reverse engineered' roxadustat data
11.09.Chicago private equity firm inks €4.1B purchase of former Sanofi generics unit Zentiva: FT
11.09.Sun's Gujarat facility put on FDA import alert for persistent production shortfalls
11.09.Sanofi, Gilead, Acadia win big at the 2025 Fierce Pharma Marketing Awards
11.09.API maker Hikal hit with FDA warning letter after repeat contamination complaints
10.09.Editor's Corner-For the first PD-1xVEGF's sake, Summit must submit to Big Pharma, stat
10.09.For pharmas looking to 'break through the clutter' and reach patients, relatability is the key
10.09.'Land mines everywhere': How pharma communications keep up under a political spotlight
10.09.Sanofi rounds up 'celebrity mom squad' for Beyfortus RSV campaign
10.09.Trump directs FDA to limit DTC drug advertising, with legal challenges sure to follow
10.09.J&J's 'practice-changing' bladder cancer drug-device combo Inlexzo lands FDA nod
10.09.Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT
10.09.Eli Lilly gives Julianne Moore a new role, signing up Oscar winner for brain health campaign
10.09.Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026
10.09.Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant
09.09.'We want to feel heard': Jamie-Lynn Sigler on how pharmas can better serve patients
09.09.Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers
09.09.Permira looks to launch $4B sale of CDMO Cambrex: FT
09.09.Novo, Lilly obesity meds 'highly cost-effective' but sure to strain payer budgets: ICER report
09.09.With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026
09.09.Endo touts Xiaflex success stories in inaugural Dupuytren's contracture awareness month